Bronstein, Gewirtz & Grossman, LLC Announces Investigation of BeiGene, Ltd. (BGNE)

NEW YORK, NY / ACCESSWIRE / September 11, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ:BGNE). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/bgne.

The investigation concerns whether BeiGene and certain of its officers and/or directors have violated federal securities laws.

On September 5, 2019, J Capital Research (“J Capital”) published a report concerning BeiGene. The J Capital report asserted, inter alia, that BeiGene “is faking sales in order to persuade investors that it can develop a successful platform in China” and that “management may also be skimming R&D and capital budgets.” On this news, BeiGene’s American depositary receipt price fell $19.95 per share, or 14.19%, over the following two trading sessions, closing at $120.61 on September 6, 2019.

If you are aware of any facts relating to this investigation, or purchased BeiGene shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/bgne. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 559300